Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · CA · Nov 23, 2009 → Mar 27, 2024
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:19 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Paul Grayson is listed as an executive officer and director on 16 SEC Form D filings by 7 issuers between Nov 2009 and Mar 2024. Largest by amount reported sold: Tempest Therapeutics, Inc. (South San Francisco, CA — other health care — 2020; $83.2M reported sold to 10 investors), Skye Bioscience, Inc. (San Diego, CA — biotechnology — 2023–2024; $62.3M reported sold to 43 investors), FATE THERAPEUTICS INC (San Diego, CA — biotechnology — 2009; $56.7M reported sold to 21 investors), BIRD ROCK BIO, INC. (La Jolla, CA — industry reported as "Other" — 2011–2017; $39.9M reported sold to 8 investors), Tentarix Biotherapeutics, LP (San Diego, CA — biotechnology — 2020–2023; $35M reported sold to 5 investors) and 2 more (all listed below).
What this means A repeat sponsor — 7 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $289.8M sold in total.
Listed alongside Andrew Schwab (8 shared filings), Bradley Bolzon (5 shared filings), Simeon George (5 shared filings), Allan Marchington (3 shared filings), Deborah Charych (3 shared filings) and 52 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Paul. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 8 bankruptcy cases matching the name listed in Key records below.
What this means 8 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 16 public filings for Paul Grayson and found 13 differences, 3 worth asking the sponsor about: Investor count went down between filings; 4 Form Ds were filed more than 15 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Paul Grayson has not run yet — it is #9,379 of 23,919 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.
Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:19 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Paul Grayson..
State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).
8 cases: 8 closed (disposition not in docket feed)
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:19 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
13 differences found between the filings for Paul Grayson — 3 worth asking about (compared 16 filings on Oct 24, 2026)
United States Bankruptcy Court, C.D. California docket "Nand Singh Garcha, Inc." filed Jul 1, 2011, closed Oct 11, 2013. Richa Nand (listed on the same filings) is listed as Debtor ("Nand Singh Garcha, Inc."). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, N.D. California docket "Giese v. U. S. Bank US Bank/NaNd" filed Jun 4, 2010, closed Dec 20, 2010. Richa Nand (listed on the same filings) is listed as Defendant ("U. S. Bank US Bank/NaNd"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, N.D. California docket "USAA Federal Savings Bank v. Karow" filed Sep 9, 2004, closed Mar 17, 2005. Margaret Karow (listed on the same filings) is listed as Defendant ("Karow"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The May 22, 2009 filing reports 14 investors; the Nov 23, 2009 Form D reports 6 investors.
What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.
Receptos, Inc. (last filing Feb 17, 2012; $11,999,999 sold of $50,000,011). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 65 days after the first sale — Tentarix Biotherapeutics, LP · Form D filed 96 days after the first sale — FullFunXn, Inc. · Form D filed 18 days after the first sale — BIRD ROCK BIO, INC. · Form D filed 20 days after the first sale — BIRD ROCK BIO, INC.
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — Tentarix Biotherapeutics, LP (latest filing Sep 16, 2020) · No amendment in the last 12 months on an offering that may still be open — Tempest Therapeutics, Inc. (latest filing Feb 12, 2020) · No amendment in the last 12 months on an offering that may still be open — BIRD ROCK BIO, INC. (latest filing Feb 3, 2016) · No amendment in the last 12 months on an offering that may still be open — FullFunXn, Inc. (latest filing Mar 26, 2015) · No amendment in the last 12 months on an offering that may still be open — BIRD ROCK BIO, INC. (latest filing Mar 31, 2014) · and 1 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Paul Grayson appears on the Dec 24, 2009 Form D/A (executive officer, director) but not on the Apr 20, 2011 Form D/A for the same offering.
What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.
Offering amount changed between filings — Tempest Therapeutics, Inc. · Offering amount changed between filings — BIRD ROCK BIO, INC. · Offering amount changed between filings — FATE THERAPEUTICS INC · Offering amount changed between filings — FATE THERAPEUTICS INC · Offering amount changed between filings — Receptos, Inc.
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
The Feb 27, 2019 filing lists a minimum of $0; the Feb 12, 2020 Form D/A lists $1.
What this means A different minimum usually means the offering terms changed. Check which terms apply to you.
listed as "Paul Grayson" on 11 filings (from Nov 23, 2009), and "Paul A. Grayson" on 5 filings (from Oct 7, 2011).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
"No Revenues" (Jun 2, 2009); then "Decline to Disclose" (Oct 7, 2011).
What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.
Address moved from La Jolla, CA to San Diego, CA — Tentarix Biotherapeutics, LP · Address moved from La Jolla, CA to San Diego, CA — FullFunXn, Inc. · Address moved from San Diego, CA to La Jolla, CA — BIRD ROCK BIO, INC. · Address moved from La Jolla, CA to San Diego, CA — FATE THERAPEUTICS INC
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
2 of 15 offerings report sales commissions totalling $5,899,371; 0 report finder's fees; 1 reports proceeds to related persons totalling $190,000. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Mar 27, 2024 D Skye Bioscience, Inc. File 021-508708 | $2,400,000 | $0 | $0 | Piper Sandler & Co BrokerCheck CRD 665 ↗ Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗ | EDGAR ↗ |
| Feb 12, 2024 D Skye Bioscience, Inc. File 021-504974 | $3,499,371 | $0 | $0 | Piper Sandler & Co BrokerCheck CRD 665 ↗ Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗ | EDGAR ↗ |
| Sep 7, 2023 D Tentarix Biotherapeutics, LP File 021-491553 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 29, 2023 D Skye Bioscience, Inc. File 021-490948 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 16, 2020 D Tentarix Biotherapeutics, LP File 021-375611 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 12, 2020 D/A Tempest Therapeutics, Inc. File 021-306741 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 9, 2017 D BIRD ROCK BIO, INC. File 021-277896 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 3, 2016 D BIRD ROCK BIO, INC. File 021-256654 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 9, 2015 D FullFunXn, Inc. File 021-249122 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 26, 2015 D FullFunXn, Inc. File 021-236670 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 31, 2014 D BIRD ROCK BIO, INC. File 021-214597 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 7, 2011 D/A BIRD ROCK BIO, INC. File 021-117838 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 7, 2011 D BIRD ROCK BIO, INC. File 021-166939 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 24, 2009 D/A FATE THERAPEUTICS INC File 021-117892 | $0 | $0 | $0 Proceeds from the offering will be used for general working capital. | None listed on this filing | EDGAR ↗ |
| Nov 23, 2009 D Receptos, Inc. File 021-131445 | $0 | $0 | $190,000 (est.) This is the sum of the budgeted salaries for the applicable executive officers for the next 12 months. | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Paul Grayson on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $62.3M from 43 investors (100% of the $40M target) as of the latest filing. Paul is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $35M from 5 investors (100% of the $35M target) as of the latest filing. Paul is listed as executive officer, director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $83.2M from 10 investors (83% of the $100.2M target) as of the latest filing. Paul is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $39.9M from 8 investors (100% of the $2.5M target) as of the latest filing. Paul is listed as executive officer, director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $667K from 4 investors (100% of the $667K target) as of the latest filing. Paul is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $56.7M from 21 investors (100% of the $32.5M target) as of the latest filing. Paul is listed as executive officer, director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $12M from 14 investors (60% of the $20M target) as of the latest filing. Paul is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Andrew Schwab is on 29 issuers in total — a repeat sponsor. Their page lists every one.
Simeon George is on 33 issuers in total — a repeat sponsor. Their page lists every one.
Bradley Bolzon is on 31 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Robert Nelsen is on 39 issuers in total — a repeat sponsor. Their page lists every one.
Amir Nashat is on 29 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Carl Weissman is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Bryan Roberts is on 32 issuers in total — a repeat sponsor. Their page lists every one.
Srinivas Akkaraju is on 12 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Jerel Davis is on 23 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
Robert Weisskoff is on 18 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Paul Grayson. Their page shows their other deals.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
None of the 7 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Paul Grayson by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 7 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Paul Grayson is listed on: none on file. No website or social profile named in Tempest Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #219,898 of 374,652 in line (1,195 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (South San Francisco, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Paul Grayson appears on a new Form D, or when a court case or SEC action is matched to them. See plans →
